HIGHLIGHTS
- who: Yong Huang from the IRCCS Institute of Neurological Sciences of Bologna (ISNB), Italy University, China have published the article: A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial, in the Journal: (JOURNAL)
- what: The phase II clinical trial of this approach showed a median RFS and OS of 11.4 months and 18.2 months, which were better than the previous reports . The increase of irradiated volume and dose to the high-risk area of microscopic glioma infiltration may be the main reason why marginal recurrence was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.